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Abstract
Treatment of xerostomia is a common clinical challenge in the oral medicine practice. Although some treatments 
have been used to improve the symptoms of xerostomia, none is completely satisfactory for the patients who suf-
fer of this alteration. In the last years non-pharmacological treatments based on electro-stimulation for the treat-
ment of xerostomia have been developed. This review is aimed at presenting new developments for the treatment 
of xerostomia, applying neuro-electro-stimulation by miniaturized intra-oral electro-stimulators. These devices 
increase salivary secretion and improve symptoms of oral dryness. Their effect is obtained by means of stimu-
lation of the lingual nerve, in whose proximity the electrodes of the apparatus are placed. The objective of this 
mechanism is both to directly stimulate the salivary glands controlled by that nerve and to enhance the salivary 
reflex. Clinical studies have been carried out that have demonstrated the wetting effect of the method described 
in this article. 
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Introduction
Xerostomia is a symptom of oral dryness that occurs 
when salivary flow is not sufficient to compensate the 
fluid loss from the oral cavity. In the majority of the 
cases it results from salivary gland hypofunction (1). 
Population studies on xerostomia are based on ques-
tionnaires that investigate if and how frequently patients 
suffer from oral dryness. According to several reports, 
its prevalence in the adult population (i.e. people report-
ing that xerostomia afflicts them always or frequently), 
ranges between 10 and a 29%, affecting more women 
than men (2,3). Xerostomia is particularly prevalent 
among adults (4). Nevertheless, an increase of cases of 
xerostomía has been recently reported among young 
adults (5).
Upon meeting dry mouth patients, dentists face a prob-
lem difficult to treat. Treatment with lubricants or sali-
vary substitutes and salivary stimulation by gustatory 
or masticatory methods may generate an improvement, 
but xerostomia recurs once the active treatment is in-
terrupted (6). Pharmacological agents, like pilocarpine 
HCl, have been studied extensively; nevertheless, more 
than one third of patients display adverse effects similar 
to those produced by other cholinergic drugs, including: 
gastric upset, perspiration, tachycardia, bradycardia, ar-
rhythmia, increases of pulmonary secretions, muscular 
tone and urinary frequency and blurred vision (7,8). In 
a recent study, individuals with xerostomia expressed 
their wish of a functional non-pharmacological method 
for their treatment; however, none of the presently avail-
able treatments fulfills these expectations (9). 
The objective of this review is to present the most rel-
evant clinical factors of xerostomia and the last ad-
vances of neuro-stimulation for its treatment, based on 
the accumulated knowledge of neurological control of 
salivary secretion. 
Most common causes of xerostomia 
Xerostomia can be caused by systemic diseases or iat-
rogenic effects. Diseases associated with salivary flow 
reduction include autoimmune diseases (particularly 
Sjögren’s Syndrome), Alzheimer’s disease, depression 
and diabetes. Infections caused by sialotrophic viruses 
such as hepatitis C virus (HCV) or human immunode-
ficiency virus (HIV), sarcoidosis, lymphoma or graft vs 
host disease can lead to inflammatory damage of sali-
vary glands, which consequently generates dysfunction 
and xerostomia (10). 
On the other hand, reduction of salivary flow can be in-
duced by medical treatments, either medication intake, 
head and neck radiotherapy, chemotherapy or bone 
marrow transplantation (11,12). Nearly 400 medicines 
may lead to xerostomia as side effect (13). Among these 
drugs, it is worthwhile to mention: anti-cholinergic, 
anti-depression, anti-psychotic, anti-hypertensive, anti-
diuretic, anti-histamine, and steroidal and non-steroidal 
anti-inflammatory agents, tranquilizers, muscular relax-
ants, and narcotic analgesics (14). The majority of those 
medications are taken during long periods of time and 
even for lifetime, and their deleterious effects increase 
along the intake period. The salivary flow is reduced 
significantly when two or more xerogenic medicines are 
taken simultaneously (15). 
Alterations in the oral cavity in patients with xe-
rostomia and hyposalivation
Xerostomía can be accompanied by a variety of chang-
es in oral hard and soft tissues. Saliva fulfils impor-
tant functions such as lubrication of the oral and oro-
pharyngeal mucosa, as well as facilitating mastication, 
swallowing and formation of the nutritional bolus. In 
average, a healthy person produces 500 ml of saliva in 
a 24 hours period. Salivary flow-rate is 0,3 ml/min in 
resting condition, but it increases to 4 or 5 ml/min dur-
ing mastication (1). The salivary fluid is crucial for de-
fense against viral, bacterial and fungal infections, for 
remineralización of dental enamel and dentine and for 
taste sensation (16,17). Reduction in salivary flow-rate 
entails a compromise in oral defense mechanisms and 
lubrication; the oral mucosa can become painful, with 
burning sensation, ulcerated and atrophic. Frequently 
an increase in the rate of dental caries with a difficult 
to treat cervical decay pattern is observed (14). Patients 
with xerostomia complain about discomfort with pros-
theses and salivary microbiological changes saliva can 
induce oral candidiasis (16,18). However, a significant 
number of patients displaying hyposalivation lack dry 
mouth symptoms, rendering the clinical diagnosis of 
xerostomia even more difficult. The presence of associ-
ated clinical signs, such as extensive dental caries and 
candidiasis, must awake the suspicion that the patient 
suffers from xerostomia. 
One of the most difficult to deal problems in patients 
with oral dryness is sleeping disturbance and conse-
quently fatigue, which deteriorates quality of life and 
leads to social isolation of the patient (19). 
Neurological control of salivary secretion 
Salivary gland secretion is regulated by the autonomic 
nervous system. Acetylcholine agonists act on parasym-
pathetic and muscarinic receptors of those exocrine glands 
inducing high electrolyte containing salivary secretion, 
whereas sympathetic stimulation produces the protein 
component of saliva. Thus, parasympathetic stimulation 
generates abundant saliva with low protein concentration 
and sympathetic stimulation produces little saliva with 
high protein concentration and viscosity (20). 
Physiologically, salivary secretion is regulated by a 
three component reflex arch including: (a) afferent re-
ceptors and nerves that carry impulses created by taste 
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and mastication activities, (b) a central connection and 
processing nucleus (salivation center), and (c) an ef-
ferent reflex arm constituted by parasympathetic and 
sympathetic nerves bundles that separately, but in co-
ordination, innervate the salivary gland blood vessels 
and acini. The afferent nerves carry impulses from the 
periphery to the salivation center in the medulla oblon-
gata, which in turn directs signals to the efferent part of 
the reflex arch leading to salivation (20,21).
The therapeutic potential of electro-stimulating nervous 
and muscular structures has been recognized in many 
areas of modern medicine. It is being used or inves-
tigated in a variety of clinical applications such as in 
bone healing or the treatment of pain, deafness, bladder 
dysfunction, cardiac arrhythmia (e.g. pacemaker), mus-
cular weakness or denervation,  problems of the respira-
tory system (e.g. phrenic nerve dysfunction), seizures, 
and essential tremor in Parkinson’s disease (22).
Given the autonomic control of salivary secretion, a 
similar principle can be used in the management of sali-
vary gland hypofunction and xerostomia. Application 
of electrical impulses on one, two or three components 
of the salivary reflex should improve both salivary se-
cretion as well as several long term consequences of 
hyposalivation. Thus, a significant increase of salivary 
flow following electrical stimulation application in ex-
perimental animals has been observed (23). Applica-
tion of an electrical current through the oral mucosa on 
afferent receptors and routes was reported in research 
projects aimed at increasing salivary flow and reducing 
oral dryness in patients with salivary gland hypofunc-
tion. It has been suggested that intra-oral electro-stimu-
lation increments salivation in resting condition via the 
salivary reflex, i.e. through the production of efficient 
amounts of afferent-efferent stimuli (24,25). 
Technological developments in salivary electro-
stimulation 
1- Mouthpiece with electrical cord  
The outcome of the first attempt to implement neuro-
electro-stimulation to increase salivary secretion was 
a device commercialized in the past in the USA (Sal-
itron, Biosonics®, PA). The apparatus consisted of a 
mouthpiece and a video cassette recorder-sized external 
control module, both parts interconnected to each other 
by an electrical cord. The mouthpiece was hold by the 
user between the dorsal side of the tongue and the palate 
for several minutes every day. It generated a signal that 
stimulated the sensorial nerves of the oral mucosa and 
resulted in increased salivation (24,26). As the clinical 
results were promising with no side-effects, the device 
was approved by the Food and Drug Administration of 
the United States (FDA) in 1988. Nevertheless, it was 
not used massively due to its large size, high price and 
cumbersomeness for the user. 
2- Self-contained electronic splint
In order to overcome the disadvantages of the Salitron® 
system, a consortium financed by the European Union 
developed a miniature intra-oral neuro-electro-stimula-
tor to stimulate salivary flow (27). 
The salivary neuro-electro-stimulator (Saliwell Gen-
Narino®) is composed by a dental thermoplastic poly-
urethane-made apparatus and an electronic miniature 
stimulating device that contains a signal generator (elec-
trodes), a battery and a circuit that is embedded within 
the plastic splint (Fig. 1). The electrodes are located on 
the third molar area mucosa to enable stimulation of the 
lingual nerve. The electro-stimulator is customized for 
each patient using the mold of its inferior dental arch. 
The system also contains a remote control that allows 
the patient to communicate with Saliwell GenNarino® 
by means of infrared light transmission at a wavelength 
of 940nm-950nm (Fig. 2). The GenNarino is similar to 
night guards to treat bruxism, is worn on the mandibu-
lar arch and is inserted and removed by the patient.
The distance between the surfaces of the electrodes and 
the lingual nerve can vary between 1 and 5 mm (28). In 
addition to the lingual nerve, also the long buccal nerve 
runs next to GenNarino’s electrodes. As a result of ex-
citing these nerves, all salivary glands are stimulated by 
the salivary reflex. Those nerves of the salivary reflex 
arch that are excited by the stimulating GenNarino are 
(underlined): 
1- Taste buds of the anterior 2/3 of the tongue →lingual 
nerve → facial nerve → salivary center, from which ef-
ferent fibers can follow 3 pathways:
a) → facial nerve→lingual nerve →submandibular and 
sublingual glands. 
b) → glossopharyngeal nerve →maxillary nerve → pa-
rotid gland.  
c) →nerves to all minor salivary glands.
2- Mucosal sensorial receptors (tactile perception) 
→lingual and long buccal nerves→ trigeminal nerve 
→ salivary center → efferent nerves to salivary glands 
according to the above description. 
The following protocol has been developed for the clini-
cal use of Saliwell GenNarino®: 
1. Before taking impression for its preparation the clini-
cian should verify that the dental, periodontal and oral 
mucosal status is optimal. 
2. This system can be used by any patient with xeros-
tomia. 
3. In head and neck irradiated patients it is recommend-
ed to place the electrodes in the side that is contra-later-
al to the irradiation area. 
4. Irradiated patients and those treated with bisphos-
phonates require special precaution to avoid irritation-
originated lesions. In case of mucosal ulceration, the 
device needs not to be worn until the lesion has healed. 
5. GenNarino can replace pharmacological therapy; in 
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severe cases though, it can be used in combination with 
sialogogues, especially in patients with dry eye. 
6. The patient must be controlled periodically. 
7. Concomitant to this therapy, it is recommended to 
deliver optimal levels of fluorides in toothpastes and 
mouthwashes. 
8. Its use in pregnant patients is not recommended. The 
use with other extra-oral electro-stimulation devices 
(e.g. pacemaker) seems to be safe. 
9. This device needs to be replaced every year, when the 
battery runs out of power.
The short term effectiveness of this electro-stimulator 
in the treatment of the xerostomia was evaluated in a 
randomized, cross-over, double blind study, comparing 
the device in active state with the same apparatus in 
inactive state among patients with dry mouth symptoms 
due to diverse causes. The main objectives of this study 
were to assess the diminution of oral dryness (objective-
ly verified by means of a wetness sensor incorporated in 
the device) and to establish improvement of symptoms 
related to xerostomia (by means of subjective measure-
ment of the perception of oral dryness symptoms). The 
results of this study demonstrated that the device was 
well tolerated by all the patients and did not cause lo-
cal or systemic adverse effects. Objective moistening 
(p<0.0001) and subjective decrease of patient-reported 
xerostomia (p<0.005) were registered (29). Thus, the 
electro-stimulator was effective in reducing oral dry-
ness by its application during 10 minutes. 
In order to confirm its long term effect and safety a 
multinational study is being carried out to evaluate its 
efficacy throughout a period of 12 months; the primary 
target is to verify if repeated neuro-electro-stimulation 
of salivary glands induces long term improvement in 
their function, as suggested in previous studies.
3- Miniature device supported by a dental implant
Some patients may require frequent and/or constant 
stimuli of salivary glands. Therefore, a dental implant-
supported miniature neuro-electro-stimulator was de-
veloped (Saliwell Crown®, Fig. 3). The use of this fixed 
apparatus avoids the disadvantage associated with the 
use of a removable device. The components of the re-
movable device were miniaturized in a small module, 
whose dimension and shape are similar to those of a 
molar tooth. It is adapted to commercially available 
dental implants. In addition, it contains a wetness sen-
sor to detect changes in intra-oral moisture. This device 
provides neuro-electro-stimulation by generating con-
tinuous or frequent stimuli in the oral cavity without 
interfering with regular oral functions. The intensity 
and frequency of stimuli is auto-regulated (increased 
or decreased) by the device’s ability to detect the oral 
wetness status, but also can be controlled by the patient 
activating the remote control.
The implant is placed in the inferior third molar area 
Fig. 1. Saliwell GenNarino electrostimulator containing 
the electronic system embedded in the plastic splint.
Fig. 2. Electro-stimulator activation by the remote con-
trol.
Fig. 3. Clinical view of the miniature electro-stimula-
tor supported by a dental implant located in the third 
molar area.
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to assure proximity to the lingual nerve and to avoid 
interference with normal oral function and cosmetic 
concerns (Fig. 3). A clinical test is ongoing, aiming at 
evaluating the long term effect of this intra-oral neuro-
electro-stimulator on salivary function and xerostomia 
symptoms. Results are promising and may render this 
salivary gland stimulating method to become the most 
convenient and safe means to treat xerostomia. 
 
Conclusions and  perspectives
Hyposalivation and xerostomia have multiple causes, 
but almost all, regardless of their aetiology, induce 
salivary flow reduction. Neuro-electro-stimulation of 
salivary glands overtakes a relevant role in therapeutic 
stimulation of salivation among patients requiring long 
term therapy and suffering from deteriorated quality 
of life. Intra-oral electro-stimulators offer a new non-
pharmacological method for the treatment of oral dry-
ness. Preliminary results showing increased salivary 
secretion and progressive improvement of xerostomia 
symptoms are demonstrating the effectiveness of these 
intra-oral devices for neuro-electro-stimulation. 
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